Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Description
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective inhibitor with of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Features
Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.